Roger Mills is the founder of Addex Therapeutics. He has over 30 years of biopharmaceutical industry experience, including roles at Acadia Pharmaceuticals.
Roger Mills serves as a Board Director and Chief Medical Officer at Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing small molecule allosteric modulators for neurological disorders. He has over 30 years of biopharmaceutical industry experience, including roles at Acadia Pharmaceuticals, Pfizer, and Gilead Sciences. Most recently, he was Executive Vice President, Development and Chief Medical Officer at Acadia Pharmaceuticals, where he oversaw a significant Phase 3 program and led the NDA submission for NUPLAZID.
Full founder directory · Investor directory · Company funding database · Fundraising library